Company Filing History:
Years Active: 2024-2025
Title: Klaus-Peter Kuenkele: Innovator in Cancer Treatment
Introduction
Klaus-Peter Kuenkele is a notable inventor based in Perchtoldsdorf, Austria. He has made significant contributions to the field of cancer treatment through his innovative research and development of polypeptides that target Wnt signaling pathways in tumor cells. With a total of two patents to his name, Kuenkele's work is at the forefront of medical science.
Latest Patents
Kuenkele's latest patents include "Polypeptides antagonizing Wnt signaling in tumor cells" and "Biparatopic polypeptides antagonizing Wnt signaling in tumor cells." The first patent provides LRP5-binding polypeptides, specifically LRP5-binding immunoglobulin single variable domain constructs that inhibit Wnt signaling pathways. This invention also details specific sequences of such polypeptides, methods of their production, and their application in treating diseases like cancer. The second patent introduces novel biparatopic LRP5/LRP6 cross-reactive binding polypeptides, which also inhibit Wnt signaling pathways. Similar to the first, this invention includes specific sequences, production methods, and treatment applications.
Career Highlights
Throughout his career, Kuenkele has worked with prominent companies in the pharmaceutical industry, including Boehringer Ingelheim International GmbH and Ablynx N.V. His experience in these organizations has contributed to his expertise in developing innovative solutions for complex medical challenges.
Collaborations
Kuenkele has collaborated with esteemed colleagues such as Vittoria Zinzalla and Marie-Ange Buyse. These partnerships have further enhanced his research and development efforts in the field of cancer treatment.
Conclusion
Klaus-Peter Kuenkele is a distinguished inventor whose work in developing polypeptides for cancer treatment showcases his commitment to advancing medical science. His patents reflect significant innovations that have the potential to improve treatment outcomes for patients suffering from cancer.